Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma

Br J Haematol. 2019 Jul;186(1):140-144. doi: 10.1111/bjh.15716. Epub 2018 Dec 11.

Affiliations

¹ Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
² Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

PMID: 30536372
DOI: 10.1111/bjh.15716

No abstract available

Keywords: daratumumab; multiple myeloma; pomalidomide; refractory; resistance.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Monoclonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Dexamethasone / therapeutic use
Drug Resistance, Neoplasm*
Female
Humans
Male
Middle Aged
Multiple Myeloma / drug therapy*
Thalidomide / analogs & derivatives
Thalidomide / therapeutic use

Substances

Antibodies, Monoclonal
daratumumab
Thalidomide
Dexamethasone
pomalidomide